KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Liabilities and Shareholders Equity (2016 - 2025)

NovoCure's Liabilities and Shareholders Equity history spans 12 years, with the latest figure at $804.3 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 35.18% year-over-year to $804.3 million; the TTM value through Dec 2025 reached $4.7 billion, down 2.84%, while the annual FY2025 figure was $804.3 million, 35.18% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $804.3 million at NovoCure, down from $1.4 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $1.4 billion in Q3 2025 and bottomed at $804.3 million in Q4 2025.
  • The 5-year median for Liabilities and Shareholders Equity is $1.2 billion (2022), against an average of $1.2 billion.
  • The largest annual shift saw Liabilities and Shareholders Equity skyrocketed 159.94% in 2021 before it crashed 35.18% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.1 billion in 2021, then increased by 4.58% to $1.2 billion in 2022, then fell by 3.82% to $1.1 billion in 2023, then rose by 8.26% to $1.2 billion in 2024, then plummeted by 35.18% to $804.3 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Liabilities and Shareholders Equity are $804.3 million (Q4 2025), $1.4 billion (Q3 2025), and $1.2 billion (Q2 2025).